Gly-β-MCA

• Product Name Alternative:

  Y-39983 (free base)

• UNSPSC Description:

  Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1].

• Target Antigen:

  Autophagy; FXR

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Metabolic Enzyme/Protease

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Gly-​_beta_-MCA.html

• Purity:

  99.75

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  C[C@@H]([C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([C@]4(CC[C@@H](O)C[C@H]4[C@H](O)[C@@H]3O)C)([H])CC[C@]12C)CCC(NCC(O)=O)=O

• Molecular Weight:

  465.62

• References & Citations:

  [1]Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  66225-78-3